1. Home
  2. GROW vs ACET Comparison

GROW vs ACET Comparison

Compare GROW & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo U.S. Global Investors Inc.

GROW

U.S. Global Investors Inc.

HOLD

Current Price

$2.67

Market Cap

33.0M

Sector

Finance

ML Signal

HOLD

ACET

Adicet Bio Inc.

N/A

Current Price

$3.20

Market Cap

33.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
GROW
ACET
Founded
1968
1947
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
33.0M
33.5M
IPO Year
1995
2017

Fundamental Metrics

Financial Performance
Metric
GROW
ACET
Price
$2.67
$3.20
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
★ $34.83
AVG Volume (30 Days)
12.1K
★ 195.4K
Earning Date
11-16-2026
11-13-2026
Dividend Yield
★ 3.36%
N/A
EPS Growth
★ 900.00
N/A
EPS
★ 0.24
N/A
Revenue
★ $14,399,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$11.22
★ N/A
Revenue Growth
★ 32.77
N/A
52 Week Low
$2.23
$0.46
52 Week High
$3.65
$9.97

Technical Indicators

Market Signals
Indicator
GROW
ACET
Relative Strength Index (RSI) 42.19 20.08
Support Level $2.49 N/A
Resistance Level $2.75 $9.51
Average True Range (ATR) 0.10 0.31
MACD 0.01 -0.00
Stochastic Oscillator 37.14 5.53

Price Performance

Historical Comparison
GROW
ACET

About GROW U.S. Global Investors Inc.

US Global Investors Inc is a registered investment advisory firm. The company manages the following business segments: Investment management services; through which the company offers, to U.S. Global Investors Funds (USGIF or the Funds) and exchange-traded fund (ETF) clients, a range of investment management products and services to meet the needs of individual and institutional investors; and Corporate Investments, through which the company invests for its own account in an effort to add growth and value to its cash position. It derives all its revenue from Investment management services.

About ACET Adicet Bio Inc.

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).

Share on Social Networks: